TY - JOUR
T1 - Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL network
AU - Klapper, Wolfram
AU - Hoster, Eva
AU - Determann, Olaf
AU - Oschlies, Ilske
AU - van der Laak, Jeroen
AU - Berger, Françoise
AU - Bernd, Heinz Wolfram
AU - Cabeçadas, José
AU - Campo, Elias
AU - Cogliatti, Sergio
AU - Leo Hansmann, Martin
AU - Kluin, Philip M.
AU - Kodet, Roman
AU - Krivolapov, Yuri A.
AU - Loddenkemper, Christoph
AU - Stein, Harald
AU - Möller, Peter
AU - Barth, Thomas E.F.
AU - Müller-Hermelink, Konrad
AU - Rosenwald, Andreas
AU - Ott, German
AU - Pileri, Stefano
AU - Ralfkiaer, Elisabeth
AU - Rymkiewicz, Grzegorz
AU - van Krieken, Johan H.
AU - Wacker, Hans Heinrich
AU - Unterhalt, Michael
AU - Hiddemann, Wolfgang
AU - Dreyling, Martin
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histo-pathological slides, has been shown to be a very powerful prognostic biomarker. The pathology panel of the European MCL Network evaluated methods to assess the Ki-67 index including stringent counting, digital image analysis, and estimation by eyeballing. Counting of 2×500 lymphoma cells is the gold standard to assess the Ki-67 index since this value has been shown to predict survival in prospective randomized trials of the European MCL Network. Estimation by eyeballing and digital image analysis showed a poor concordance with the gold standard (concordance correlation coefficients [CCC] between 0.29 and 0.61 for eyeballing and CCC of 0.24 and 0.37 for two methods of digital image analysis, respectively). Counting a reduced number of lymphoma cells (2×100 cells) showed high interobserver agreement (CCC=0.74). Pitfalls of the Ki-67 index are discussed and guidelines and recommendations for assessing the Ki-67 index in MCL are given.
AB - Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histo-pathological slides, has been shown to be a very powerful prognostic biomarker. The pathology panel of the European MCL Network evaluated methods to assess the Ki-67 index including stringent counting, digital image analysis, and estimation by eyeballing. Counting of 2×500 lymphoma cells is the gold standard to assess the Ki-67 index since this value has been shown to predict survival in prospective randomized trials of the European MCL Network. Estimation by eyeballing and digital image analysis showed a poor concordance with the gold standard (concordance correlation coefficients [CCC] between 0.29 and 0.61 for eyeballing and CCC of 0.24 and 0.37 for two methods of digital image analysis, respectively). Counting a reduced number of lymphoma cells (2×100 cells) showed high interobserver agreement (CCC=0.74). Pitfalls of the Ki-67 index are discussed and guidelines and recommendations for assessing the Ki-67 index in MCL are given.
UR - http://www.scopus.com/inward/record.url?scp=77950398416&partnerID=8YFLogxK
U2 - 10.1007/s12308-009-0036-x
DO - 10.1007/s12308-009-0036-x
M3 - Journal articles
AN - SCOPUS:77950398416
SN - 1865-5785
VL - 2
SP - 103
EP - 111
JO - Journal of Hematopathology
JF - Journal of Hematopathology
IS - 2
ER -
